The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Efficacy of first-line (1L) immunotherapy (IO)-based regimens in patients with sarcomatoid and/or rhabdoid (S/R) metastatic non-clear cell renal cell carcinoma (nccRCC): Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
 
Chris Labaki
Research Funding - Roche/imCORE
 
Ziad Bakouny
Honoraria - UpToDate
Research Funding - Bristol-Myers Squibb (Inst); Genentech/Roche (Inst)
 
Audreylie Lemelin
No Relationships to Disclose
 
Matthew Scott Ernst
No Relationships to Disclose
 
Kosuke Takemura
Other Relationship - The Yasuda Medical Foundation
 
J Connor Wells
No Relationships to Disclose
 
Sumanta Kumar Pal
Travel, Accommodations, Expenses - crispr therapeutics; Roche
 
Bernadett Szabados
Honoraria - Ellipses Pharma; Ipsen; Merck; Roche/Genentech
Travel, Accommodations, Expenses - Roche/Genentech
 
Benoit Beuselinck
Consulting or Advisory Role - AstraZeneca (Inst); Bristol-Myers-Squibb (Inst); IPSEN (Inst); Merck KGaA (Inst); Pfizer (Inst)
Speakers' Bureau - Bristol-Myers-Squibb (Inst); Bristol-Myers-Squibb (Inst); Ipsen (Inst); Merck (Inst); Pfizer (Inst)
Research Funding - Bristol-Myers-Squibb (Inst)
Travel, Accommodations, Expenses - Ipsen (Inst); Ipsen (Inst); Pfizer (Inst)
 
Rana R. McKay
Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Caris Life Sciences; Dendreon; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Telix Pharmaceuticals; Tempus; Vividion Therapeutics
Research Funding - Bayer (Inst); Pfizer (Inst); Tempus (Inst)
 
Jae-Lyun Lee
Stock and Other Ownership Interests - Amgen; Black Diamond Therapeutics; Innovent Biologics; Johnson & Johnson/Janssen; Karyopharm Therapeutics; Merck; Zymeworks
Honoraria - AstraZeneca; Bristol-Myers Squibb; MSD
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Merck; Oscotec; Sanofi
Research Funding - Amgen (Inst); AstraZeneca/MedImmune (Inst); Bayer Schering Pharma (Inst); Bristol-Myers Squibb (Inst); GI Innovation (Inst); Janssen (Inst); MSD (Inst); Novartis (Inst); Oscotec (Inst); Pfizer (Inst); Roche/Genentech (Inst); Seagen (Inst)
 
Takeshi Yuasa
No Relationships to Disclose
 
Francis Parnis
Stock and Other Ownership Interests - Telix Pharmaceuticals
Consulting or Advisory Role - Ipsen; Janssen Oncology; Merck Serono
Speakers' Bureau - AstraZeneca
Other Relationship - Bayer Schering Pharma
 
Georg A. Bjarnason
Honoraria - Bristol-Myers Squibb; Eisai; Ipsen; Merck; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Eisai; Ipsen; Pfizer
Research Funding - Merck (Inst); Pfizer (Inst)
 
Bradley Alexander McGregor
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Calithera Biosciences; Eisai; EMD Serono; Exelixis; Genentech/Roche; Merck; Pfizer; Seattle Genetics/Astellas
Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)
 
David A. Braun
Stock and Other Ownership Interests - Fortress Biotech (subsidiary)
Consulting or Advisory Role - Abbvie; Adept Field Solutions; Aptitude Health; AVEO; Blueprint Partnership; Bristol-Myers Squibb; Catenion; Cello Health; Charles River Associates; Dedham Group; Defined Health; Exelixis; Insight Strategy; Octane Co.; Schlesinger Associates; Slingshot Insights; Targeted Oncology; Trinity Group
Research Funding - AstraZeneca; Exelixis
Travel, Accommodations, Expenses - Bristol-Myers Squibb
 
Wanling Xie
Consulting or Advisory Role - Convergent Therapeutics
 
Wenxin Xu
Consulting or Advisory Role - Exelixis; Jazz Pharmaceuticals
 
Daniel Yick Chin Heng
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer
Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)
 
Toni K. Choueiri
Stock and Other Ownership Interests - Curesponse; Osel; Pionyr; Precede Bio; Tempest Therapeutics
Honoraria - Honoraria and Advisory/Consultancy are same
Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate
Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)
Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)
Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate
Other Relationship - Medical writing and editorial assistance support may have been funded by Communications companies funded by pharmaceutical companies such as ClinicalThinking, Health Interactions, Envision Pharma Group, Fishawack Group of Companies, Parexel